Related Experiment Video
Updated: Mar 16, 2026
12:24
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
13.3K
Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas
Jozef Malysz1, Patrick Erdman1, Jeremy Klapper2
1Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, PA.
Clinical Lymphoma, Myeloma & Leukemia
|August 14, 2016
Summary
Brentuximab vedotin shows promise for treating aggressive B-cell lymphomas expressing CD30. This study found CD30 in a significant portion of diffuse large B-cell lymphomas and other aggressive types, suggesting potential benefits of this targeted therapy.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- FDA approval of brentuximab vedotin for CD30-positive lymphomas spurred research into other lymphoma types.
- CD30 expression is a key factor in targeted therapy for certain relapsed or refractory lymphomas.
Purpose of the Study:
- To evaluate CD30 expression in various aggressive B-cell lymphomas.
- To assess the potential benefit of brentuximab vedotin treatment in these lymphomas.
Main Methods:
- Analysis of 116 aggressive B-cell lymphoma cases diagnosed between 2000 and 2012.
- Investigated CD30 expression in specific lymphoma subtypes including DLBCL, Burkitt lymphoma, and others.
Main Results:
- CD30 expression was detected in 37.5% of diffuse large B-cell lymphomas (DLBCL).
- CD30 was found in 46.2% of other non-DLBCL aggressive B-cell lymphomas.
Conclusions:
- CD30 expression in DLBCL and other aggressive B-cell lymphomas suggests brentuximab vedotin as a potential targeted therapy.
- The absence of MYC-driven proliferation in most cases further supports brentuximab's efficacy in CD30-positive subsets.
